Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acorda Therapeutics, Inc.
Acorda Therapeutics Provides 2009 Business and Pipeline Update at 27th Annual JPMorgan Healthcare Conference
January 30th, 2009
Acorda Therapeutics, Inc. (Nasdaq: ACOR) President and CEO Ron Cohen, M.D. will provide an update on the Company’s U.S. and European commercialization and regulatory filing strategy for its lead product, Fampridine-SR, today at the JPMorgan Healthcare conference in San Francisco, CA. In addition, Dr. Cohen will discuss timelines for advancing the Company’s preclinical pipeline candidates into clinical trials and provide an update on the Zanaflex franchise. Fampridine-SR Updates Acorda remains on track to file a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) in the first quarter of 2009, as well as a centralized Marketing Authorization Application (MAA) with the...
Source: Health Business Week (2009-01-30)
|
